Research Analysts Offer Predictions for SPRB Q1 Earnings

Spruce Biosciences, Inc. (NASDAQ:SPRB) – Stock analysts at HC Wainwright upped their Q1 2026 EPS estimates for shares of Spruce Biosciences in a report issued on Tuesday, March 10th. HC Wainwright analyst R. Selvaraju now forecasts that the company will post earnings per share of ($8.92) for the quarter, up from their prior estimate of ($10.46). HC Wainwright currently has a “Buy” rating and a $200.00 target price on the stock. The consensus estimate for Spruce Biosciences’ current full-year earnings is ($1.00) per share. HC Wainwright also issued estimates for Spruce Biosciences’ Q2 2026 earnings at ($8.20) EPS, Q3 2026 earnings at ($8.08) EPS, Q4 2026 earnings at ($7.56) EPS, FY2026 earnings at ($32.66) EPS and FY2027 earnings at ($14.12) EPS.

Spruce Biosciences (NASDAQ:SPRB) last announced its quarterly earnings results on Thursday, March 12th. The company reported ($9.58) EPS for the quarter, missing analysts’ consensus estimates of ($9.16) by ($0.42).

A number of other equities analysts have also weighed in on SPRB. Weiss Ratings reiterated a “sell (e+)” rating on shares of Spruce Biosciences in a research note on Monday, December 29th. Wall Street Zen downgraded Spruce Biosciences from a “hold” rating to a “sell” rating in a research note on Saturday, December 27th. Leerink Partners raised Spruce Biosciences from a “market perform” rating to an “outperform” rating and set a $160.00 price objective on the stock in a report on Wednesday, December 3rd. Oppenheimer began coverage on Spruce Biosciences in a research report on Tuesday, December 23rd. They set an “outperform” rating and a $283.00 price objective on the stock. Finally, Citizens Jmp dropped their target price on Spruce Biosciences from $180.00 to $170.00 and set a “market outperform” rating for the company in a report on Tuesday. Four equities research analysts have rated the stock with a Buy rating, three have issued a Hold rating and one has given a Sell rating to the stock. Based on data from MarketBeat, the stock has a consensus rating of “Hold” and an average target price of $170.10.

Spruce Biosciences Stock Down 6.7%

Shares of SPRB stock opened at $59.90 on Thursday. Spruce Biosciences has a 12-month low of $4.28 and a 12-month high of $240.00. The company has a market capitalization of $82.06 million, a PE ratio of -1.16 and a beta of 3.62. The firm has a 50 day moving average price of $70.75 and a two-hundred day moving average price of $75.74.

Institutional Trading of Spruce Biosciences

Large investors have recently modified their holdings of the stock. Carlyle Group Inc. acquired a new position in Spruce Biosciences in the third quarter valued at about $24,765,000. Boothbay Fund Management LLC acquired a new stake in Spruce Biosciences during the fourth quarter worth about $4,175,000. Caligan Partners LP bought a new position in Spruce Biosciences in the 4th quarter valued at about $1,787,000. ADAR1 Capital Management LLC bought a new position in Spruce Biosciences in the 4th quarter valued at about $5,052,000. Finally, Schonfeld Strategic Advisors LLC acquired a new position in shares of Spruce Biosciences in the 4th quarter valued at approximately $2,157,000. 91.71% of the stock is owned by institutional investors and hedge funds.

Spruce Biosciences Company Profile

Spruce Biosciences, Inc is a clinical-stage biopharmaceutical company dedicated to developing therapies for rare endocrine and dermatological disorders. Headquartered in San Diego, California, Spruce focuses on conditions with significant unmet medical needs, employing a precision medicine approach to identify and advance treatment candidates through late-stage clinical trials.

The company’s lead asset, tildacerfont, is an oral corticotropin-releasing factor type 1 (CRF1) receptor antagonist being evaluated for the treatment of congenital adrenal hyperplasia (CAH), a genetic disorder characterized by insufficient cortisol production and excess androgen levels.